These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 21146988)
1. Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome. Manning DD; Cioffi CL; Usyatinsky A; Fitzpatrick K; Masih L; Guo C; Zhang Z; Choo SH; Sikkander MI; Ryan KN; Naginskaya J; Hassler C; Dobritsa S; Wierschke JD; Earley WG; Butler AS; Brady CA; Barnes NM; Cohen ML; Guzzo PR Bioorg Med Chem Lett; 2011 Jan; 21(1):58-61. PubMed ID: 21146988 [TBL] [Abstract][Full Text] [Related]
2. The discovery of diazepinone-based 5-HT3 receptor partial agonists. Manning DD; Guo C; Zhang Z; Ryan KN; Naginskaya J; Choo SH; Masih L; Earley WG; Wierschke JD; Newman AS; Brady CA; Barnes NM; Guzzo PR Bioorg Med Chem Lett; 2014 Jun; 24(11):2578-81. PubMed ID: 24755431 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome. Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963 [TBL] [Abstract][Full Text] [Related]
4. Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome. Yoshida S; Shiokawa S; Kawano K; Ito T; Murakami H; Suzuki H; Sato Y J Med Chem; 2005 Nov; 48(22):7075-9. PubMed ID: 16250667 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model. Tamaoki S; Yamauchi Y; Nakano Y; Sakano S; Asagarasu A; Sato M J Pharmacol Exp Ther; 2007 Sep; 322(3):1315-23. PubMed ID: 17540858 [TBL] [Abstract][Full Text] [Related]
7. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Spiller RC Curr Opin Pharmacol; 2011 Feb; 11(1):68-74. PubMed ID: 21398180 [TBL] [Abstract][Full Text] [Related]
8. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Meyers NL; Hickling RI Drugs R D; 2008; 9(1):37-63. PubMed ID: 18095752 [TBL] [Abstract][Full Text] [Related]
9. 5-HT(3) receptors: potential of individual isoforms for personalised therapy. Niesler B Curr Opin Pharmacol; 2011 Feb; 11(1):81-6. PubMed ID: 21345729 [TBL] [Abstract][Full Text] [Related]
10. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies. Johanson JF Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419 [TBL] [Abstract][Full Text] [Related]
16. [Role of serotonin in the pathophysiology of the irritable bowel syndrome]. Moskwa A; Boznańska P Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558 [TBL] [Abstract][Full Text] [Related]
17. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Ren TH; Wu J; Yew D; Ziea E; Lao L; Leung WK; Berman B; Hu PJ; Sung JJ Am J Physiol Gastrointest Liver Physiol; 2007 Mar; 292(3):G849-56. PubMed ID: 17110521 [TBL] [Abstract][Full Text] [Related]
19. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. Zou BC; Dong L; Wang Y; Wang SH; Cao MB Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178 [TBL] [Abstract][Full Text] [Related]
20. Serotonergic agents and the irritable bowel syndrome: what goes wrong? Spiller R Curr Opin Pharmacol; 2008 Dec; 8(6):709-14. PubMed ID: 18672092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]